About the KYRA Study

Help Discover Ways to Live More Dynamically With Narcolepsy

By participating in research for narcolepsy type 2 (NT2), you can take steps toward finding ways for more productive days. Help researchers rewrite the narrative on sleep disorder treatments—join the KYRA Study today.

See If You May Qualify

About the KYRA Study

Help Discover Ways to Live More Dynamically With Narcolepsy

See If You May Qualify

You may be able to participate in the KYRA Study if you:

Are 18–70 years of age

Have a diagnosis of NT2

Have a BMI between 16 and 38 kg/m²

If you are interested in participating, the study doctor or team will review additional study criteria with you.

Qualified participants will receive their assigned study medication (investigational drug or placebo) and study-related care at no cost. Participants may be reimbursed for travel and expenses.

See If You May Qualify

About the KYRA Study

Narcolepsy without cataplexy (sudden loss of muscle tone), or NT2, can impose a significant burden on daily life. Researchers are working to identify treatment options that may help individuals with this disorder.

The KYRA Study is evaluating the safety and effectiveness of an investigational drug for NT2. During the study, participants will complete up to 10 scheduled study visits over the course of up to 25 weeks, including overnight stays. Study participation will be divided into the following periods:

Screening Period

The screening period lasts up to 45 days before the start of study treatment. During this time, participants will undergo various tests and assessments to determine their eligibility for the study. This includes a review of medical history, a physical examination, and completion of questionnaires about sleep patterns and narcolepsy symptoms.

Study Treatment Period

For the first part of the treatment period, participants will be randomly assigned to receive either the investigational drug or a placebo (a substance that looks like the investigational drug but does not contain any active ingredients). During the latter part of the treatment period, all participants will receive the investigational drug. Throughout the study, participants will complete various study tests and procedures.

Neither participants nor the study team will know if participants are receiving the investigational drug or a placebo during the first part of the treatment period. The treatment period will last up to 12 weeks.

Follow-Up Period

After completing the treatment period, participants will enter a follow-up period lasting 4 weeks. During this time, participants will have 2 follow-up visits scheduled approximately 1 week and 4 weeks after their last dose of the study drug. These visits will involve monitoring health status and any potential side effects.

Long-Term Extension Period

Participants may be invited to join a long-term extension study. If eligible, participants would receive the investigational drug for a longer duration. Participation in the extension study is voluntary. The long-term extension provides an opportunity for researchers to gather additional information about the safety and effectiveness of the investigational drug over an extended period.

You can play a role in helping researchers find more ways to study and treat NT2 by participating in this clinical research study.

See If You May Qualify

Your Participation Matters

Research has shown that certain diseases and drugs may affect people differently based on several factors, including age, sex assigned at birth, race, and ethnic background. For this reason, it is important that people from all backgrounds be involved in medical research. This can help to ensure that potential new drugs are safe and work well for all people impacted by the disease being studied.

About the KYRA Study

The KYRA Study is evaluating the safety and effectiveness of an investigational drug for NT2. Participants will be randomly assigned to receive either the investigational drug or a placebo (a substance that looks like the investigational drug but does not contain any active ingredients) for the first 8 weeks of the study treatment period. For the final 4 weeks, all participants will receive the investigational drug. Throughout the study, participants will complete various study tests and procedures.

Neither participants nor the study team will know if participants are receiving the investigational drug or a placebo during the first 8 weeks. Participants will complete up to 10 scheduled study visits, including some overnight visits. The total study duration will be up to 25 weeks.

You can play a role in helping researchers find more ways to study and treat NT2 by participating in this clinical research study.

Your Participation Matters

Idiopathic Hypersomnia

Clinical Research Study

Home The ALBA Study The KYRA Study

See If You May Qualify

Privacy Notice Terms and Conditions Cookie Policy Accessibility Statement